Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 538 participants.
Also called NCT01459809
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 538 participants
- Sponsor
- Registry
-
NCT01459809
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Algeria, Colombia, Egypt, Guatemala, India, Iran, Lebanon, Mexico, Russia, South Africa, Tunisia, Türkiye, Ukraine, United Arab Emirates
- Registry status
- Completed
Technical summary
Registry record NCT01459809. Randomized; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2014-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
- Acronym
- RECOMMEND
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- GLIMEPIRIDE
- Intervention (Drug)
- METFORMIN
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01459809- Content hash
48c3b5c17be652da33f5c2c95bc7418792dce7c598628b51eed41e244f0d237c